IMC – an integrative review

This paper reviews and integrates extant work in the integrated marketing communication (IMC) literature. With this in mind, three alternative and widely disseminated conceptual frameworks proposed in the IMC literature are employed as a starting point. The review locates important points of theoretical intersection among these three frameworks, and drawing on the wider literature, develops and cross-fertilizes them into IMC constructs. The review then combines the constructs into an integrative framework by proposing theory-driven relationships and formalizing them using testable propositions. The final outcome offers a clearer synthesis and re-conceptualization of IMC

Idiopathic distal sensory polyneuropathy: ACTTION diagnostic criteria

Objective: To present standardized diagnostic criteria for idiopathic distal sensory polyneuropathy (iDSP) and its subtypes: idiopathic mixed fiber sensory neuropathy (iMFN), idiopathic small fiber sensory neuropathy (iSFN), and idiopathic large fiber sensory neuropathy (iLFN) for use in research. Methods: The Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities and Networks (ACTTION) public-private partnership with the Food and Drug Administration convened a meeting to develop consensus diagnostic criteria for iMFN, iSFN, and iLFN. After background presentations, a collaborative, iterative approach was used to develop expert consensus for new criteria. Results: An iDSP diagnosis requires at least one small fiber (SF) or large fiber (LF) symptom, at least one SF or LF sign, abnormalities in sensory nerve conduction studies (NCS) or distal intra-epidermal nerve fiber density (IENFD), and exclusion of known etiologies. An iMFN diagnosis requires that at least one of the above clinical features is SF and one clinical feature is LF. Diagnostic criteria for iSFN require at least one SF symptom and at least one SF sign with abnormal IENFD, normal sensory NCS, and the absence of LF symptoms and signs. Diagnostic criteria for iLFN require at least one LF symptom and at least one LF sign with normal IENFD, abnormal NCS, and absence of SF symptoms and signs. Conclusions: Adoption of these standardized diagnostic criteria will advance research and clinical trials and spur development of novel therapies for iDSPs.